Clinical trial
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00849056 |
|---|---|
| Title | Safety and Efficacy of Albiglutide in Type 2 Diabetes |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Biological, Drug |
| Interventions | albiglutide, placebo |
| Enrollment | 310 |
| Start date | Jan 1, 2009 |
| Primary completion | Nov 1, 2011 |
| Completion | Jan 1, 2013 |
| First posted | Feb 23, 2009 |
| Last update posted | Jan 9, 2017 |
| Countries | India, Peru, South Africa, South Korea, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: